Mösges R, et al. - Researchers assessed the safety, efficacy and immune mechanisms of short-course treatment with adjuvant-free Lolium perenne peptides (LPP) following a 6-week dose-escalation protocol. In this study, it appeared safe to increase the doses of subcutaneous LPP. Furthermore, as a result of increasing doses of subcutaneous LPP, substantially diminished reactivity to conjunctival provocation test (CPT) as well as induction of blocking antibodies as early as 4 weeks after treatment initiation was noted.